ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Novel Wide-Spectrum Virucidal Lipid Nanoparticles.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Wide-Spectrum Virucidal Lipid Nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Viral infections remain a global health challenge, highlighting the urgent need for innovative antiviral strategies. Broad-spectrum antivirals offer a promising solution. Virustatic compounds fail due to their reversible mechanisms, while existing virucidal agents are frequently limited by toxicity. Here, POSTAN, a novel, biocompatible virucidal lipid nanoparticle engineered for direct antiviral activity is presented. Composed of polyoxyethylene sorbitan oleate (PO) and sodium taurodeoxycholate (ST), POSTAN mimics heparan sulfate (HS) proteoglycans and lipid rafts-host cell structures commonly exploited by viruses for attachment. POSTAN demonstrates optimal physicochemical properties for pulmonary delivery, minimal to no toxicity in Vero cells and human airway epithelial (HAE) cultures, and a favorable safety profile in neonatal mice. It exhibits broad-spectrum virucidal activity at micromolar concentrations against herpes simplex virus (HSV), respiratory syncytial virus (RSV), Zika virus, Chikungunya virus (CHIKV), and SARS-CoV-2 by disrupting viral envelopes. In HAE cultures, POSTAN reduced SARS-CoV-2 titers by 5- and 3-log before and after infection. In a neonatal RSV mouse model, intranasal POSTAN led to 6-, 10-, and 19-fold reductions in lung viral titers following prophylactic, therapeutic, or combined prophylactic and therapeutic treatments. It mitigated lung pathology and prevented hemorrhage. These findings support POSTAN as a safe, effective, broad-spectrum antiviral platform for respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.